Scarica l'app Stockscreener
3.85
1.28%
-0.05
Pre-mercato:
3.95
0.10
+2.60%
Precedente Chiudi:
$3.90
Aprire:
$3.87
Volume 24 ore:
1.00M
Relative Volume:
0.31
Capitalizzazione di mercato:
$438.97M
Reddito:
$884.00K
Utile/perdita netta:
$-103.64M
Rapporto P/E:
-2.761
EPS:
-1.3944
Flusso di cassa netto:
$-95.45M
1 W Prestazione:
-14.63%
1M Prestazione:
-12.90%
6M Prestazione:
+41.03%
1 anno Prestazione:
+55.87%
Intervallo 1D:
$3.83
$3.98
Intervallo di 1 settimana:
$3.77
$4.708
Portata 52W:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.85 | 438.97M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
89.46 | 155.82B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.73 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
80.00 | 102.71B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.50 | 83.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.98 | 48.42B | 6.30B | 1.07B | 1.34B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Piper Sandler | Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-10 | Iniziato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field - Seeking Alpha
BlackRock stake in Perspective Therapeutics (CATX): 5.25M shares - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics, Inc. to Provide Corporate Updates and Financial Results in May 2026 - Quiver Quantitative
Perspective Therapeutics to Provide Several Upcoming Corporate Updates - The Globe and Mail
Perspective Therapeutics maps out May updates, Q1 results on May 11 - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX) and UnitedHealth (UNH) - The Globe and Mail
CATX (Perspective Therapeutics Inc.) slips 1.41% after reporting Q4 2025 EPS that misses analyst estimates by 40.3%.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics reports interim trial results for NET therapy By Investing.com - Investing.com India
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
CATX Reiterates by Wedbush -- Price Target Maintained at $11 - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap UpShould You Buy? - MarketBeat
[212Pb]VMT-α-NET Shows Promising Safety and Efficacy in Advanced Neuroendocrine Tumor Phase I/IIa Trial (Data Cutoff March 2026) - Minichart
Perspective Therapeutics (CATX) Updates Clinical Trial Results f - GuruFocus
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX) - MarketBeat
Perspective Therapeutics reports interim trial results for NET therapy - Investing.com
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial - marketscreener.com
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - The Manila Times
Perspective Therapeutics posts updated Phase 1/2a [212Pb]VMT-α-NET data showing 43% response in Cohort 2 - TradingView
[8-K] Perspective Therapeutics, Inc. Reports Material Event - Stock Titan
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics Inc. R (AAJ0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView — Track All Markets
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - Stock Titan
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
CATX Rallies on Merger News - Xã Thanh Hà
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
1.14%
Capitalizzazione:
|
Volume (24 ore):